Arcturus Therapeutics Holdings Inc. Stock News

Moderna (MRNA) stock just pulled back to a long-term bullish trendline on the charts , and has cheap options to boot

Wall Street analysts forecast that Moderna Inc (NASDAQ:MRNA) will report earnings per share (EPS) of ($0.36) for the current quarter, Zacks Investment Research reports. Five analysts have issued estim

Novavax, Inc (NASDAQ: VAX) announced Tuesday its novel coronavirus (COVID-19) vaccine elicited "robust antibody responses" in participants of the Phase 1...

The Nasdaq Composite is once again leading the major indexes higher. Investors are hoping more news later this week around unemployment could help extend the gains.

MorphoSys receives FDA approval for Monjuvi. Brigham president tenders resignation from Moderna board after conflict of interest.

Jefferies analyst estimates the biotech’s Phase 3 trial has a 65% chance of working.

The BioNTech/Pfizer team has launched its Phase 2/3 clinical trial in the USA and internationally for its COVID-19 vaccine on July 27, 2020, after excellent Phase 1/2 clinical trial results.

Indigo Agriculture, a company dedicated to harnessing nature to help farmers sustainably feed the planet, announces the closing of $360M in additional

There are many small biotechs developing experimental COVID-19 therapies and vaccine candidates. Arcturus' market cap now tops $1 billion. Arcturus announced in March that it was teaming up with Duk

We still expect the economy to remain on a recovery path but it will not be as quick as earlier assumed.

The Past Week, In A Nutshell What Happened: Stocks closed the week practically unchanged after mixed reactions to a slew of blow-out earnings results. Remember This: “...

SAN DIEGO, July 31, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development

A look at the shareholders of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) can tell us which group is most...

The deal appears to price the vaccine at less than $10.50 a dose.

Moderna Inc (NASDAQ: MRNA), which commenced a late-stage trial of its mRNA vaccine, codenamed mRNA-1273, against SARS-CoV-2 earlier in the week, has been reportedly targeted...